Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight

Description:

The market for Non Hodgkin Lymphoma has significant unmet medical necessities in terms of demand for innovative drugs and novel technologies. This is one of the major factors behind the market witnessing rapid growth in Non Hodgkin Lymphoma segment. Past few decades have witnessed an increased level of activity with regards to development of new identification systems and drug mechanisms. In recent years, there have been an increasing number of pharmaceutical companies focusing their efforts on developing better and highly effective therapeutics for Non Hodgkin Lymphoma which are likely to occupy major market share in coming years.

Monoclonal antibodies (mAbs) for the treatment of Non Hodgkin Lymphoma has occupied large portion in global market. The highly versatile nature of mAbs makes them suitable for targeting different sub-categories of Non Hodgkin Lymphoma which is modestly provided by other therapeutics. The market of widely used chemotherapeutics is likely to decrease further as they are less effective and have more side effects as compared to mAbs. Present market shows that pharmaceutical companies are trying to capture large market portion by increasing indication of already available mAbs for other cancer categories.

Targeted therapies for Non Hodgkin Lymphoma have been able to make a significant place in global market. These therapeutics are generally based on inhibitors which targets signaling in the cancerous cells. Ibrutinib kinase inhibitor developed by Pharmacyclics and Johnson and Johnson's sub-division Janssen Pharmaceuticals got market approval by the FDA in 2013 for the treatment of mantel cell lymphoma. In 2014, this drug also got the FDA's approval for chronic lymphocytic leukemia in US market. It is expected that more targeted therapeutics will be available in coming years that would be able to provide effective medical care to patients and generate higher revenues for pharmaceutical companies.

The concepts of personalized cancer vaccines for Non Hodgkin Lymphoma have started emerging in global therapeutic market. These vaccines are widely accepted by oncologists and patients for having higher safety and efficacy levels. However, issues pertaining higher costs of newly developed personalized cancer vaccine is expected to decrease in near future. Technological advances have created higher confidences in pharmaceutical companies to make these medicines at higher manufacturing rates. This capability will help them to increase the market penetration of Non Hodgkin Lymphoma cancer vaccines.

With the recent technological advances, stem cell transplant has emerged as potent method for the treatment and cure of Non-Hodgkin. Oncologists are still trying to decipher the underlying principal of stem cell therapeutics as a treatment strategy. This method is expected to emerge as major section in market as the benefits provided outmatches any other products. It is expected that pharmaceutical companies would be able to overcome barriers in coming years before market introduction.

The market of Non Hodgkin Lymphoma is expected to make steady growth in coming years due to raising incidences and introduction of new therapeutics by pharmaceutical companies in global market. This largely untapped market has yet to witness the products which would be able to prevent, cure this disease, decrease morbidity and mortality rates. Large amount of money invested in research and development has started to show positive effect on pharmaceutical industry. As a result, the introductions of large amount of therapeutic products in coming years are expected to increase global market size of Non Hodgkin Lymphoma therapeutics.

"Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight" Report Highlight:

- Global Non Hodgkin Lymphoma Market Overview
- Mechanism of Non Hodgkin Lymphoma Therapeutics
- Global Non Hodgkin Lymphoma Pipeline by Type, Phase & Company
- Global Non Hodgkin Lymphoma Pipeline: 204 Drugs
- Majority of the Drugs are in Phase-I: 54 Drugs
- Marketed Drugs for Non Hodgkin Lymphoma: 30 Drugs
- Patent Analysis by Country, Year & Compositions
Contents:

1. Introduction to Non Hodgkin Lymphoma
   1.1 Low Grade Non Hodgkin Lymphomas
   1.2 High Grade Non Hodgkin Lymphomas

2. Mechanism of Non Hodgkin Lymphoma Therapeutics

3. Global Non Hodgkin Lymphoma Market Overview
   3.1 Current Market Scenario
   3.2 Global Non Hodgkin Lymphoma Clinical Pipeline Overview

4. Global Non Hodgkin Lymphoma Market Dynamics
   4.1 Favorable Market Parameters
   4.2 Market Growth Challenges
   4.3 Future Growth Outlook

5. Follicular Lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country
   5.1 Research till Phase-III
   5.2 Discontinued Drug in Pipeline

   6.1 Research till Registration
   6.2 Marketed Drugs Clinical Insight
   6.3 Suspended & Discontinued Drugs in Clinical Pipeline

7. B-Cell Lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country
   7.1 Preclinical till Phase-II
   7.2 Discontinued Drugs in Clinical Pipeline

8. Mantle Cell Lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country
   8.1 Preclinical till Phase-II
   8.2 Discontinued Drugs in Clinical Pipeline

9. Cutaneous T Cell Lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country
   9.1 Preclinical till Phase-II
   9.2 Marketed Drug Clinical Insight
   9.3 Discontinued Drugs in Clinical Pipeline

10. Cutaneous B-Cell Lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country
    10.1 Phase: Preclinical

11. Diffuse Large B Cell Lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country
    11.1 Preclinical till Phase-II
    11.2 Discontinued Drugs in Clinical Pipeline

12. T Cell Lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country
    12.1 Preclinical till Phase-II
    12.2 Marketed Drugs Clinical Insight
    12.3 Discontinued Drugs in Clinical Pipeline

13. Mycosis Fungoides Clinical Pipeline Insight by Phase, Indication, Company & Country
    13.1 Phase-I
    13.2 Marketed Drugs Clinical Insight

    14.1 Phase-II

15. Multiple Non Hodgkin Lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country
    15.1 Preclinical till Registration
    15.2 Marketed Drugs Clinical Insight
    15.3 Discontinued Drugs in Clinical Pipeline

16. Competitive Landscape
    16.1 Aryogen Biopharma
16.2 Biogen Idec
16.3 Biovest International
16.4 Chugai Pharmaceutical
16.5 Genetech
16.6 ImmunoGen
16.7 Johnson & Johnson
16.8 Novartis
16.9 Pfizer
16.10 Roche

Figure 1-1: Types of Blood Cancer
Figure 1-2: Identification of Different Types of Lymphomas
Figure 1-3: Classification Systems for Non Hodgkin Lymphoma
Figure 1-4: Grading of Non Hodgkin Lymphomas
Figure 1-5: Classification of Low Grade Non Hodgkin Lymphomas
Figure 1-6: Classification of High Grade Non Hodgkin Lymphomas

Figure 2-1: Mechanism of Monoclonal Antibodies for the Treatment of Non Hodgkin Lymphoma
Figure 2-2: Mechanism of Kinase Inhibitors for Treating Non-Hodgkin Lymphoma
Figure 2-3: Mode of Action of Non Hodgkin Lymphoma Vaccines

Figure 3-1: Non-Hodgkin Lymphoma Therapeutics Market (US$ Billion), 2014-2020

Figure 6-1: Follicular Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 6-2: Follicular Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 6-3: Discontinued Follicular Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 6-4: Discontinued Follicular Lymphoma Clinical Pipeline by Phase (Number), 2014

Figure 6-5: Non Hodgkin Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 6-6: Non Hodgkin Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 6-7: No Development Reported in Non Hodgkin Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 6-8: No Development Reported in Non Hodgkin Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 6-9: Discontinued Non Hodgkin Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 6-10: Discontinued Non Hodgkin Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 6-11: Suspended Non Hodgkin Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 6-12: Suspended Non Hodgkin Lymphoma Clinical Pipeline by Phase (Number), 2014

Figure 6-13: B-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 6-14: B-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 6-15: No Development Reported in B-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 6-16: No Development Reported in B-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 6-17: Discontinued B-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 6-18: Discontinued B-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014

Figure 6-19: Mantle-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 6-20: Mantle-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 6-21: Cutaneous T-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 6-22: Cutaneous T-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 6-23: Discontinued Cutaneous T-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 6-24: Discontinued Cutaneous T-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014

Figure 6-25: Diffuse Large B-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 6-26: Diffuse Large B-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 6-27: Discontinued Diffuse Large B-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 6-28: Discontinued Diffuse Large B-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014

Figure 6-29: T-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 6-30: T-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014

Figure 6-31: Mycosis Fungoides Clinical Pipeline by Phase (%), 2014
Figure 6-32: Mycosis Fungoides Clinical Pipeline by Phase (Number), 2014

Figure 6-33: Multiple Non Hodgkin Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 6-34: Multiple Non Hodgkin Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 6-35: Discontinued Multiple Non Hodgkin Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 6-36: Discontinued Multiple Non Hodgkin Lymphoma Clinical Pipeline by Phase (Number), 2014

Figure 4 1: Drivers for Non- Hodgkin Lymphoma Market
Figure 4 2: Challenges for Non- Hodgkin Lymphoma Market

Ordering:
Order Online - [http://www.researchandmarkets.com/reports/3038280/](http://www.researchandmarkets.com/reports/3038280/)
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>Non Hodgkin Lymphoma Therapeutics Market &amp; Pipeline Insight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/3038280/">http://www.researchandmarkets.com/reports/3038280/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SCBRPAPZ</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 2400</td>
</tr>
<tr>
<td>CD-ROM:</td>
<td>USD 2800 + USD 58 Shipping/Handling</td>
</tr>
<tr>
<td>Hard Copy:</td>
<td>USD 3600 + USD 58 Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 4800</td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr ☐</th>
<th>Mrs ☐</th>
<th>Dr ☐</th>
<th>Miss ☐</th>
<th>Ms ☐</th>
<th>Prof ☐</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td>__________________________</td>
<td>Last Name:</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address:</td>
<td>*</td>
<td>Job Title:</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td>__________________________</td>
<td>Address:</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td>__________________________</td>
<td>Postal / Zip Code:</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td>__________________________</td>
<td>Phone Number:</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World